Search Results

<< Back to podcast list Strategic Partner(s) Dr. Bryan Roth About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Your complete guide to AGPCR24. Inside, you’ll find the schedule, speaker bios, venue map, travel tips, and essential information to make the most of your workshop experience. OFFICIAL BOOKLET Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF You can also download the booklet by scanning this QR code

The Practical Assessment of Signaling Bias Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Home → Flash News → 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles ✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 8, 2025 Category Dr. GPCR Courses 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics✅ PK-PD Modeling – Predicting drug behavior, non-linear PK✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi About Dr. Nagarajan Vaidehi "Nagarajan Vaidehi, Ph.D., is professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research Institute of the City of Hope in Los Angeles, CA. She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi received her Ph.D. in quantum chemistry from the Indian Institute of Technology in India, where she was honored with the Distinguished Alumni Award in 2016. Following her postdoctoral studies on protein dynamics simulation methods at University of Southern California, and at Caltech, she became the director of biomolecular simulations at the Materials and Process Simulation Center, Beckman Institute at Caltech. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair of DCQM in 2018. She has advanced the use of computational methods to meet the challenges of designing therapeutics with lower off target effects. She is an internationally recognized biophysicist for her contributions in developing constrained molecular dynamics simulation methods with emphasis on application to G-protein coupled receptors and drug design." Dr. Nagarajan Vaidehi on the web City of Hope Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! Published on October 22, 2024 Category GPCR Weekly News GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/germline-mutations-in-a-g-protein-identify-signaling-cross-talk-in-t-cells #GPCR #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Simone Prömel & Dr. Ines Liebscher About Dr. Simone Prömel Simone Prömel is currently a professor of cell biology at the Heinrich Heine University Düsseldorf, Germany. Being a biochemist by training, she completed her Ph.D. at the Institute of Biochemistry at the University of Oxford, UK. During this time, she discovered her love for Adhesion GPCRs and started delineating the molecular mechanisms of the Adhesion GPCR Latrophilin-1. These extraordinary receptors, about which there was not much known other than that they are huge and somehow play important roles in health and disease, fascinated her so much that she continued working on them when she started her own lab at Leipzig University. There she focused on the different modes of action of Adhesion GPCRs and found that they do not only mediate classical G protein signals into cells but can also communicate solely via their N termini. Today, she and her team are working on the questions of how Adhesion GPCRs integrate the different signals on a molecular level and how these are translated into physiological functions in various model organisms. Together with Ines Liebscher, Simone is leading an EU-funded COST Network on Adhesion GPCRs: CA18240 Adher´n Rise. Dr. Simone Prömel on the web Prömel Lab Pubmed Researchgate Twitter Dr. GPCR Ecosystem About Dr. Ines Liebscher Dr. Liebscher is a Professor at the Rudolf Schönheimer Institute of Biochemistry at the Medical Faculty of the Leipzig University. During her medical studies in Leipzig, she had her first encounter with an orphan GPCR as the subject of her MD thesis. Being faced with the vast unknown biochemical and pharmacological territory that would be helpful to study orphan receptors she enrolled in the MD/Ph.D. program of Leipzig University. Her postdoctoral work leads her to investigate a whole family of orphan receptors: adhesion GPCRs. With the little knowledge on these receptors available, there were multiple questions to tackle. Starting with proving and characterizing G-protein coupling, Ines spends several years studying the activation mechanism of adhesion GPCRs. In collaboration with great fellow adhesion GPCR scientists around the globe she established a tethered agonist -extracellular matrix- mechano-activation- activation scenario that forms the basis for her current projects that focus on the structural and physiological implications of these findings. Together with Simone Prömel, Ines is leading a COST Network on adhesion GPCRs: CA18240 Adher'nRise. Dr. Ines Liebscher on the web Website LinkedIn Researchgate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Explore the scientific conference program at DrGPCR for cutting-edge insights in GPCR research. Stay updated with our program today! Welcome to Flash News—your fastest track to the latest updates in GPCR research, pharmacology, and biotechnology. Stay informed with breaking news, announcements, and key industry trends—all published here before they appear on social media. 🚀 Want full access? Become Premium! Unlock exclusive resources like the University Vault, in-depth courses, and weekly insights that go beyond the headlines. 👉 Become Premium Strategic Partners Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal December 8, 2025 Read full article Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery A GPCR imaging breakthrough that didn’t start in a grant proposal December 3, 2025 Read full article It started with a cold email. A young chemist, Dr. Johannes Broichhagen, was asked if he could synthesize a molecule “when you’re back in Munich.” That small moment pulled him into islet biology, confocal imaging, and a collaboration that would reshape how GLP-1R is visualized in real tissue. The new blog takes you behind the scenes — the London trip, the early confocal experiments, the pivot to chemical probes, and the trust-driven partnership that sparked a new era in GPCR imaging. If you care about chemical biology, receptor visualization, or building tools that actually work in complex systems, this one is worth reading. 🔗 Read the full story : https://www.ecosystem.drgpcr.com/post/how-collaboration-sparked-a-gpcr-imaging-breakthrough-in-chemical-biology Visualizing GPCRs in their native environment changes everything December 2, 2025 Read full article This week on The Dr. GPCR Podcast , we bring you Episode 2 of our three-part series with Celtarys Research — featuring chemist Dr. Johannes Broichhagen , whose work is redefining how we image GPCRs in real tissue. His team’s chemical probes enabled high-resolution GLP-1R visualization across systems — from pancreatic islets to in vivo two-photon imaging. Inside the episode: Chemical probes vs antibodies: specificity, stability, and live-cell performance Mapping GPCR surface pools with precision Tissue-level insights reshaping metabolic disease research What’s next: multiplex receptor labeling + AI-designed tools If GLP-1R biology, receptor trafficking, or advanced imaging are part of your work, this conversation belongs on your radar. 🎧 Listen to Episode 2 → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/chemical-probes-for-gpcr-imaging-and-internalization And stay tuned for Episode 3 with Celtarys. #GPCR #DrGPCR #metabolism #GLP1R #receptorbiology #fluorescenceimaging #drugdiscovery How GPCR Collaboration Built an Innovation Engine November 16, 2025 Dr. GPCR Podcast Read full article Collaboration isn’t a soft skill — it’s an innovation strategy. At Monash Institute of Pharmaceutical Sciences, a quiet experiment challenged the traditional PI-silo model: no private labs, shared infrastructure, pooled funding, and student rotations. The result? An ecosystem where GPCR innovation accelerated — not because of a single star scientist, but because the system itself made collaboration unavoidable. “No one had their own lab. That meant no one could build a fiefdom — and everyone had to talk.” — Michelle Halls This structure: Multiplied research capacity Attracted talent and funding Created a durable innovation hub This is more than a story — it’s a blueprint for GPCR science, biotech R&D, and CRO partnerships. 🎧 Listen to the full episode: Leadership, Luck, and GPCR Signaling 🔓 Learn more: Dr. GPCR Premium #GPCR #DrGPCR #DrugDiscovery #Innovation #ScienceLeadership #Collaboration Scientific careers aren’t just built on brilliance November 14, 2025 Dr.GPCR Podcast Read full article Scientific careers aren’t just built on brilliance—they’re shaped by curiosity, timing, and paying close attention. In this conversation, Michelle Halls reminds us of something every scientist eventually learns: hard work is essential, but noticing the unexpected often defines your biggest breakthroughs. She also names a truth we rarely acknowledge out loud—luck and timing matter. Many talented scientists leave the field not because they lacked skill, but because the right opportunity didn’t land at the right time. And that’s why attention to detail, persistence, and a bit of serendipity can change the trajectory of a research career. 🎧 Watch this moment — then catch the full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR Why does it matter where signaling happens inside a cell? November 13, 2025 Dr.GPCR Podcast Read full article Why does it matter where signaling happens inside a cell? This moment cuts straight to the heart of how many of us fell in love with GPCR biology — that realization that signaling isn’t random. It’s structured, organized, and spatially constrained. Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. This shift — from thinking about “pathways” to understanding localized signaling architecture — is what drove her to build a research career around spatial control of GPCR signaling. This isn’t just academic. The way signals are organized defines specificity, drug response, and potential for targeted therapies. If you work with GPCRs, this perspective changes how you design experiments and interpret data. 🎧 Watch this insight — or listen to the full conversation with Michelle.🔗 Full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling ✨ Join Premium: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR From Pipettes to Platforms: The Evolution of GPCR Research November 13, 2025 Dr. GPCR Podcast Read full article Back when GPCR assays were performed with single channel pipettes, failure wasn’t cheap. Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive. Today, automation and high-throughput platforms make it easy to forget how fragile discovery used to be. But that history matters. It shaped how we design experiments, make decisions, and lead teams. In this week’s Dr. GPCR Podcast blog, we unpack: How the manual era shaped experimental discipline Why technology changed what we ask, not just how we ask How scientists grow from technicians to strategic leaders 🎧 Read the full story and listen to the episode: https://www.ecosystem.drgpcr.com/post/from-pipettes-to-platforms-the-evolution-of-gpcr-research 🔓 Join Dr. GPCR Premium for deeper tools and insights: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR #DrugDiscovery #Pharmacology #Biotech How GPCR Spatial Signaling Sparked a Scientific Journey November 12, 2025 Dr. GPCR Podcast Read full article When boredom met obsession. It started as a summer project.A reluctant student pipetting through the day, expecting nothing more than routine lab work. But for Michelle Halls, that first experiment flipped everything. One spark led to a PhD at Monash University, a fellowship at University of Cambridge, and eventually a leadership role at the forefront of GPCR spatial signaling — a field reshaping how we understand receptor biology and drug discovery. Michelle’s story isn’t just about science.It’s about what happens when curiosity takes over. From reluctant intern to scientific leader From local signaling to spatial pharmacology From spark to strategy Read the full story here🔗 https://www.ecosystem.drgpcr.com/post/how-gpcr-spatial-signaling-sparked-a-scientific-journey 🔓 Want deeper GPCR insights? Join Dr. GPCR Premium for exclusive content, expert access, and community. #GPCR #DrGPCR #SpatialSignaling #Pharmacology #DrugDiscovery #ScientificLeadership #Biotech Every receptor tells a story November 11, 2025 Dr.GPCR Podcast Read full article Every receptor tells a story — but GPCRs speak a language of organization. Dr. Michelle Halls unpacks how GPCR signaling isn’t just about ligand–receptor interaction. It’s about where and how signaling happens — spatially confined microdomains, scaffolding proteins, and preassembled complexes that fine-tune the cell’s response. This level of organization defines specificity in signaling, and understanding it changes how we think about drug targeting and disease mechanisms. It’s a moment that reframes GPCR biology from static pathways to dynamic, organized systems — where complexity is the key to precision. 🎧 Watch this moment from our conversation, then listen to the full episode on leadership, luck, and GPCR signaling: 👉 https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR How sensitive can a GPCR really be? November 9, 2025 Dr. GPCR Podcast Read full article Think femtomolar. That’s the scale we’re talking about. This week on the Dr. GPCR Podcast , we sit down with Michelle Halls , leader of the Spatial Organisation of Signalling lab at Monash University. Her team is redefining how we understand GPCR signaling — not just at the cell surface, but in space, time, and disease context. In this episode, you’ll learn: How GPCR pre-assembly enables femto-level signal detection. Why receptor location matters as much as receptor type. How disease can hijack signaling organization — and what that means for drug discovery. Michelle’s work bridges elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling 🎓 Explore Dr. GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery #receptors #biotech #signaltransduction AI is changing how we think about structure, function, and discovery November 4, 2025 Dr. GPCR Podcast Read full article AI is changing how we think about structure, function, and discovery — but Jens Carlsson reminds us: the real test isn’t whether we can explain today’s data, it’s whether we can predict tomorrow’s results . In this clip, Jens unpacks a mindset shift that every computational scientist should hear. For decades, molecular modeling focused on explaining — rationalizing why a ligand binds, why a mutation shifts signaling, why a simulation behaves a certain way. But explaining is retrospective. Prediction is transformative. With tools like AlphaFold , his lab can now model receptor–peptide complexes in seconds — an achievement that once took months. Yet Jens’s caution stands: prediction must be proven. A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new function. That’s where the future of GPCR research lies — not in describing the past, but in anticipating it. Whether you’re running simulations, screening compounds, or designing next-gen molecules, this insight reframes what “success” in computational pharmacology really means. 👉 Watch the full episode: model predict discover #GPCR #DrGPCR If your model can’t change an experiment, what’s the point? October 31, 2025 Dr. GPCR Podcast Read full article If your model can’t change an experiment, what’s the point? That’s the standard Dr. Jens Carlsson sets in his lab at Uppsala University. For him, modeling isn’t just about elegant simulations; it’s about impact . The kind of impact that shows up in how experiments are designed, which compounds get prioritized, and what gets synthesized next. Carlsson’s lab doesn’t work in isolation. They collaborate deeply with medicinal chemists, pharmacologists, and biotech partners to create workflows that connect virtual screening to synthesis and bioassay. Every step has a purpose. Every prediction feeds into a testable hypothesis. But the real differentiator? The way they collaborate: strategically, transparently, and without ego. His team is clear about the capabilities and limitations of their models, an honesty that builds long-term trust across disciplines. In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional fluency is no longer optional. It’s the catalyst for turning insight into innovation. 🎧 Learn how Carlsson turns models into translational outcomes in this episode of the Dr. GPCR Podcast: model predict discover #DrGPCR #GPCR #CollaborationInScience #ComputationalChemistry #Pharmacology #DrugDesign “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” October 30, 2025 Terry's Corner Read full article “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” In our AMA, Terry Kenakin shared timeless career advice for young pharmacologists navigating a fast-changing field: “Try to keep a finger on the pulse of as much as you can… that was one of the main reasons for doing Terry’s Corner. New ideas come up, and if we can encapsulate them and expose them, you can just hit a button, hear about it, and pursue it.” To stay relevant in the next decade, it’s not about chasing the latest assay or tool. It’s about building adaptive thinking—knowing where the field is moving and being ready to pivot with it. That’s what Terry’s Corner was built for: a space to turn decades of industry experience into short, targeted insights that keep you ahead of the curve. 🟢 Join Terry’s Corner → https://www.ecosystem.drgpcr.com/terry-corner ✳️ Next AMA Session: ⚠️ Today, Oct 30 | 12–1 PM EST #GPCR #DrGPCR #Pharmacology #DrugDiscovery #CareerDevelopment #Biotech #Mentorship #EarlyDiscovery #ScientificLeadership What happens when 40+ years of discovery experience get distilled into one conversation? October 29, 2025 Terry's Corner Read full article What happens when 40+ years of discovery experience get distilled into one conversation? That’s exactly what our first-ever AMA session with Terry Kenakin set out to do. Terry’s Corner was built to make advanced pharmacology practical: a space where scientists don’t just learn passively—they shape the curriculum and bring their toughest questions forward. As Terry shared during the AMA: “This is a labor of love. Pharmacologists are almost always working in systems they don’t fully understand. The more we can see, the better choices we make.” Through live Q&A, targeted modules, and short, focused lessons, Terry’s Corner gives discovery teams the frameworks to: Decode complex GPCR signaling. Rethink outdated models. Translate early data into better decisions. This is more than another course. It’s an open vault of knowledge. 🟢 Read More → https://www.ecosystem.drgpcr.com/post/accelerating-gpcr-drug-discovery-what-40-years-of-pharmacology-reveal ✳️ Next AMA Session: October 30 | 12–1 PM EST #GPCR #DrGPCR #Pharmacology #DrugDiscovery #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR&D #BiotechInnovation Ask-Me-Anything Session - Sept 18 - Trailer October 28, 2025 Terry's Corner Read full article Pharmacology doesn’t stand still—and neither should your toolkit. In the discovery phase, one overlooked kinetic parameter or a misjudged model can set your team back months . Precision in early decisions determines whether your molecule moves forward or stalls. That’s why we’ve built a dedicated space inside Terry’s Corner to get clear, evidence-based answers to the questions that shape your experiments and strategy. In this AMA session, you’ll learn how to: Decode GPCR signaling complexity using functional assay strategies Identify allosteric modulators before they derail downstream decisions Integrate kinetics early—before your program locks into costly pathways Rethink legacy screening frameworks through modern pharmacology This isn’t theory. It’s 45+ years of applied discovery experience from Terry Kenakin distilled into practical, modular lessons designed for scientists who need clarity fast. 🟢 Join Terry’s Corner → Terry's Corner | Dr. GPCR Ecosystem ✳️ BONUS — Live AMA Session: Get direct, unfiltered access to Terry. Bring your most challenging questions to our next Ask Me Anything session on October 30, 12–1 PM EST . ⚠️ Seats are limited. Don’t fall behind on what will shape the next decade of discovery. #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Biotech #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR&D #BiotechInnovation Irreversible kinetics = strategic lever in drug design. October 27, 2025 Terry's Corner Read full article Receptor pharmacology has evolved. Irreversible interactions are no longer niche curiosities — they’re strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery. Inside Terry’s Corner, you’ll gain access to focused, high-impact modules built for teams who need to engineer binding kinetics, not just potency . These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the tools to make smarter decisions earlier in the pipeline. Here’s what’s covered in this week’s lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic durability, and influence dosing intervals. Structured tissue penetration challenges — why high-affinity molecules stall at the periphery and how to optimize kinetic profiles for deeper reach. Quantifying irreversible activity (K_inact / K_I) — turning persistent binding into measurable design parameters that guide candidate optimization. Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault and stay ahead of the curve: ✳️ Courses by Terry | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Kinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDevelopment Can your model actually predict the outcome of a GPCR experiment? October 27, 2025 Dr. GPCR Podcast Read full article “Explain” is no longer enough. Can your model actually predict the outcome of a GPCR experiment? At Uppsala University, Dr. Jens Carlsson and his team are redefining what computational modeling means in drug discovery. Their lab doesn’t just simulate receptor-ligand interactions after the fact; they aim to forecast receptor behavior before the first assay is run. By integrating molecular docking, molecular dynamics, and machine learning, they design ligands with the goal to anticipate biological outcomes. This kind of predictive modeling challenges the traditional role of computation in pharmacology, where models have too often served as post hoc rationalizations. But Carlsson’s lab stands out for another reason: knowing when not to predict. His team is candid about the limits of their models. If the resolution isn't good enough, or if the data is too uncertain, they’re not afraid to say, “We don’t know.” That scientific humility (combined with deep collaborations with medicinal chemists and pharmacologists) is exactly what makes their predictions so useful. This episode is essential listening for anyone thinking seriously about translational pharmacology and the future of GPCR drug discovery. 🎧 Explore how predictive modeling is reshaping GPCR science in this Dr. GPCR Podcast episode: model predict discover #DrGPCR #GPCR #MolecularModeling #PredictivePharmacology #DrugDiscovery Persistent binding ≠ just covalent. October 24, 2025 Terry's Corner Read full article Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Dr. GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs October 23, 2025 GPCR Weekly News Read full article This week’s Weekly News breaks down how to control target engagement—so duration, penetration, and PK/PD separation serve your program, not sink it. Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “irreversible” in real systems, anticipating PK/PD decoupling, and using k_inact/K_I when Ki falls short. 🔹 Podcast Spotlight: Dr. Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where AlphaFold still needs a chaperone). If you’re advancing covalent or tight-binding candidates—or building models meant to predict, not narrate —this edition is built to shorten cycles and reduce surprises. Read the full Weekly News ➤ https://bit.ly/3KVlL4m If it helps your team, share it forward. #DrGPCR #GPCR Model. Predict. Discover. – Podcast Episode Release October 22, 2025 Dr. GPCR Podcast Read full article What if a failed experiment became the best thing that ever happened to your career? Dr. Jens Carlsson started his journey aiming to be a biotech engineer. But during a summer internship in protein purification, he faced a harsh reality: lab work wasn’t his strength. The experiments didn’t work, the data didn’t flow, and it was frustrating. But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why things weren’t working. A professor noticed and called it out in a recommendation letter. That unexpected moment of clarity redirected his path. Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based modeling to predict GPCR-ligand interactions, before they’re ever tested in the lab. The mindset shift? Stop explaining experiments after they happen. Start designing them to happen. His journey is a powerful reminder that the right career often reveals itself through “failure.” Follow what lights you up. Notice where your mind naturally goes. And don’t ignore the signs, it might be your real path calling. 🎧 Listen to Jens’ full story on the Dr. GPCR Podcast : https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover #DrGPCR #GPCR #CareerInScience #ComputationalBiology #DrugDiscovery #PhDLife 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 ... 7 🔔 Don’t Just Stay Updated—Stay Ahead Flash News gives you a glance at what’s happening right now in the GPCR world. But to go deeper—with full presentations, expert courses, and exclusive resources—you’ll need more than just a headline. 🎓 Go Premium and unlock: 200+ expert presentations in the University Vault Weekly News with in-depth insights Exclusive courses and masterclasses 👉 Upgrade to Premium Today

Home → Flash News → New cryo-EM insights reveal how extracellular domains communicate with transmembrane regions in holo-adhesion GPCRs, uncovering mechanisms behind receptor activation. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/adhesion-gpcrs/conformational-coupling-between-extracellular-and-transmembrane-domains-modulates-holo-adhesion-gpcr-function #gpcr #drgpcr Published on January 7, 2025 Category GPCR Weekly News New cryo-EM insights reveal how extracellular domains communicate with transmembrane regions in holo-adhesion GPCRs, uncovering mechanisms behind receptor activation. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/adhesion-gpcrs/conformational-coupling-between-extracellular-and-transmembrane-domains-modulates-holo-adhesion-gpcr-function #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → The Dr. GPCR Podcast is back! After a long break, a new episode will be released today 🎧 Join us in 2025 with a year filled with GPCRs, as we share with specialists about their career paths, the latest breakthroughs, their advice, and inspiring stories. 📅 Ep. 157 drops today January 9th at 10 AM EST. Don’t miss it! ✅ Stay tuned & subscribe at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-157-with-dr.-nagarajan-vaidehi Published on January 9, 2025 Category Dr. GPCR Podcast The Dr. GPCR Podcast is back! After a long break, a new episode will be released today 🎧 Join us in 2025 with a year filled with GPCRs, as we share with specialists about their career paths, the latest breakthroughs, their advice, and inspiring stories. 📅 Ep. 157 drops today January 9th at 10 AM EST. Don’t miss it! ✅ Stay tuned & subscribe at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-157-with-dr.-nagarajan-vaidehi Previous Next Recent Articles

Home → Flash News → Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Published on June 2, 2025 Category GPCR Weekly News Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Jennifer Pluznick About this episode Dr. Pluznick discovered that olfactory receptors in mice are also expressed in their kidneys and blood vessels. Her research is focused on the role of chemosensory GPCRs in regulating renal and cardiovascular function, and identifying renal/cardiovascular olfactory receptor ligands, and relating them to whole-animal physiology. This work contributes to a better understanding of how the kidney helps maintain homeostasis in humans. Jennifer is currently an assistant professor of physiology at the Johns Hopkins School of Medicine. She received her undergraduate degree in biology from Truman State University and earned her Ph.D. in renal physiology from the University of Nebraska Medical Center. She then spent five years training as a postdoctoral fellow in the laboratory of Michael Caplan at Yale University, where she studied both renal physiology and sensory biology systems and focused on olfaction. Dr. Jennifer Pluznick on the web John Hopkins Pluznick Lab Pubmed Ted Talk Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 10, 2025 Category Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery , you know that finding a promising candidate is just the start. A drug must also:✅ Be absorbed into the body✅ Reach the right target✅ Stay long enough to be effective✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Sri Kosuri About Dr. Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology, functional genomics, and bioinformatics over the last 20 years. He is passionate about developing more rational ways to understand and engineer biology. Sri is a co-founder at Octant and an Associate Professor at UCLA in the Chemistry and Biochemistry Department. His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry, human genetic variation, gene regulation, chemical biology, synthetic biology, and functional genomics. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of Joule Unlimited, an engineered algal biofuel company. He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering at MIT and BS in Bioengineering at UC Berkeley. Sri is originally from New Jersey, Philadelphia, and Kansas and was born in North Carolina. He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr. Sri Kosuri on the web Octant Kosuri Lab Twitter LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Started in medicinal chemistry. Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. A thesis project, a mentor’s advice, and a leap during the pandemic changed everything. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRcommunity #DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation Published on June 19, 2025 Category Dr. GPCR Podcast Started in medicinal chemistry. Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. A thesis project, a mentor’s advice, and a leap during the pandemic changed everything. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRcommunity #DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation Previous Next Recent Articles Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift 👉 In early-stage biotech , uncertainty is not an exception. It is the environment. The science evolves, assumptions break, and timelines shift quietly rather than dramatically. Most founders are prepared for this on a technical level. What they are less prepared for is how much this uncertainty tests the team. Early hiring decisions are usually made around skills, experience, and domain expertise. That feels logical. 👉 Complex biology seems to demand strong credentials. Bu Attila Foris 5 days ago The One Reason Why Biotech Startups Fail More Often Than They Should Biotech startups rarely fail all at once. They fail while everyone is still working hard. Experiments continue. Meetings happen. Progress is reported. Yet alignment fades and decisions lose clarity. This is not a motivation problem. It is structural. When complexity grows faster than strategy, biotech companies drift. Survival depends less on science and more on whether clarity scales with complexity. Attila Foris Jan 7 Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris Dec 31, 2025 The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025

<< Back to podcast list Strategic Partner(s) Dr. Debbie Hay About this episode Dr. Debbie Hay is presently a professor at the Department of Pharmacology and Toxicology at the University of Otago after spending 18 years at the University of Auckland. Her work is primarily focused on class B GPCRs and their interactions with RAMPs. Debbie obtained a Ph.D. in Molecular Pharmacology from Imperial College London in the UK. She has gained experience from working in academia and at GSK as an industrial trainee. Join me and learn more about Debbie’s career and what she learned through her experiences as a scientist. Dr. Debbie Hay on the web LinkedIn Wikipedia University of Otago University of Auckland Google Scholar Pubmed Research Gate Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research Published on March 15, 2025 Category Dr. GPCR Courses 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development —and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance✅ PK-PD modeling & therapeutic profiles✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research Previous Next Recent Articles

Home → Flash News → Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! Cutting-edge cryo-EM reveals how LYCHOS, a lysosomal protein, senses cholesterol to regulate metabolism and cell growth ➡️https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/cryo-em-reveals-cholesterol-binding-in-the-lysosomal-gpcr-like-protein-lychos #gpcr #drgpcr Published on February 4, 2025 Category GPCR Weekly News Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! Cutting-edge cryo-EM reveals how LYCHOS, a lysosomal protein, senses cholesterol to regulate metabolism and cell growth ➡️ https:// www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/cryo-em-reveals-cholesterol-binding-in-the-lysosomal-gpcr-like-protein-lychos #gpcr #drgpcr Previous Next Recent Articles !

<< Back to podcast list Strategic Partner(s) Dr. Alix A. J. Rouault About Dr. Alix A. J. Rouault "My contribution to science began during the equivalent of U.S. masters training at the Université de Bretagne Occidentale (UBO; France). Under the leadership of Dr. Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe hemorrhage. During this time, Dr. Olivier Mignen , the director of another research unit at the UBO recommended me to Dr. Julien Sebag , a researcher at the University of Iowa. I spent two years working with Dr. Sebag as an exchanged scholar while my student visa was in the work, during which time I thoroughly reviewed the literature on the melanocortin receptor accessory protein 2 (MRAP2), resulting in my first peer-reviewed publication in Biochimica et Biophysica Acta (BBA). I then undertook my first project where I demonstrated that MRAP2 regulates the signaling of multiple G protein-coupled receptors (GPCRs) through different structural regions. This project yielded my first, first author publication in BBA – Molecular Cell Research, and a book chapter for Neuromethods on a technique I adapted to measure the mitochondrial pyruvate oxidation in primary neurons. In 2017 I officially joined the PhD program in the Department of Molecular Physiology and Biophysics at the University of Iowa Carver College of Medicine, under the mentorship of Dr. Sebag. During my PhD, I continued my studies on MRAP2. I contributed to an In-vivo project that showed that MRAP2 regulates the growth hormone secretagogue receptor-1a (GHSR1a), the results of which are published in Nature Communications. Concurrently, I described the mechanisms by which MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay. At the time, NanoBiT was a prototype technology we gained access to by collaborating with Promega. This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to an activated GPCR for the first time. Using this novel technique, I showed that MRAP2 biased GHSR1a signaling and shut down its constitutive activity; this work resulted in a first author publication in Science Signaling. While writing my thesis, I published another paper in the Journal of Biological Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed the C-terminal gate theory. This theory states that the post-translational modification of GHSR1a’ C-terminal tail is not a docking space for the arrestins, but rather a necessary modification leading to a structural change granting the arrestins access to the core of the receptor. Some of my data were also used in an In-vivo study published in iScience, showing the relevance of the MRAP2 regulatory effect on GHSR1a in pancreatic islets. Dr. Cone’s lab was a clear choice for a postdoc. Dr. Cone was the first to clone the melanocortin receptors (the GPCRs that led to the discovery of MRAP2), and his lab works is highly In-vivo oriented. Since I joined the lab, I became proficient in many In-vivo techniques, I adapted my arrestin recruitment assay to a high throughput screening format for drug discovery, I have started molecular work on the melanocortin receptors. I also invested a tremendous amount of time in developing my leadership skills. I spent time running for the chair of International Affairs for the U-M Postdoctoral Association (UMPDA). Further, I applied to create a scientific session at the American Physiology Summit (APS) 2024 dedicated to GPCR biased signaling. Dr. Lauren Slosky and Dr. Joshua Gross were enthusiastic about the idea and jumped on board. Our session was picked up by the APS. We were pleasantly surprised by the interest generated by our scientific session, Dr. Michel Bouvier accepted to open our session and will be followed by Dr. John McCorvy , Dr. Dylan Eiger , and Joshua Gross. We are very excited about this event. At this point in my career, I am creating connections with biomedical industry, assessing professional opportunities, and seriously weighing strengths of career options across sectors; however, academia does not make information about industry widely accessible to trainees. This is, in part, why I ran for, and was elected Chair of International Affairs of the University of Michigan Postdoc Association. I want to connect more trainees with diverse career resources to support professional decision-making. I am hopeful that my efforts to support the professional opportunities of my peers, in combination with my own scientific endeavors, will inform my future career decisions." Dr. Alix A. J. Rouault on the web University of Michigan Carver College of Medicine ResearchGate Google Scholar Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Complex Allosteric Cannabinoid Receptor Pharmacology Date & Time Friday, November 3rd / 11:30 AM Abstract Coming Soon About Robert Laprairie "Dr. Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development at the College of Pharmacy and Nutrition, University of Saskatchewan. Robert was the President and Director of Education for the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and the 2021 Recipient of the William A. Devane Young Investigator Award from the International Cannabinoid Research Society (ICRS). Robert and his lab have been interested in the molecular pharmacology of cannabinoids for nearly 10 years and he has published more than 50 studies in the field." Robert Laprairie on the web University of Saskatchewan Pubmed Twitter Instagram ResearchGate Google Scholar Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Dylan Eiger About Dylan Eiger Dylan Eiger is currently an MD/Ph.D. student at Duke University School of Medicine. He received his B.S. in Chemistry from Duke University in 2016 where he worked in the lab of Dr. Stephen Craig and studied polymer chemistry and material science. He is currently finishing his Ph.D. in the lab of Dr. Sudarshan Rajagopal, a former postdoctoral fellow of Dr. Robert J. Lefkowitz . Dylan's graduate research focuses on the mechanisms underlying biased signaling at GPCRs, specifically, the role of differential receptor phosphorylation (phosphorylation barcodes) and subcellular GPCR signaling in directing functionally selective responses. He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus serves as an endogenous example of biased agonism. After finishing his MD/Ph.D., Dylan plans to complete his residency training in Internal Medicine and subsequently pursue fellowship training in Cardiology. He hopes to continue his research on biased agonism at GPCRs with a particular focus on the treatment of cardiovascular disease. Dylan Eiger on the web LinkedIn Twitter PubMed Website Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → In case you haven’t heard, Dr. Terry Kenakin will soon start the course Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection 📖 The five-lecture series describes essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic opportunity. Published on October 22, 2024 Category Dr. GPCR Courses In case you haven’t heard, Dr. Terry Kenakin will soon start the course Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection 📖 The five-lecture series describes essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic opportunity. ✳️ Register today! https://www.ecosystem.drgpcr.com/advanced-methods-for-the-optimization-of-candidate-selection #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → Some biotech stories start in the lab. Celtarys started with a thesis project, a new chemical strategy, and a vision to make fluorescence available for drug discovery. Now, they’re growing fast and partnering with Dr. GPCR to connect with the researchers who need them most. ✳️ Learn more about the partnership: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRcommunity #ScienceCollaboration #FluorescentLigands #BiotechStartup Published on July 2, 2025 Category Celtarys - Media Partner Some biotech stories start in the lab. Celtarys began to with a thesis project, a new chemical strategy, and a vision to make fluorescence available for drug discovery. Now, they’re growing fast and partnering with Dr. GPCR to connect with the researchers who need them most. ✳️ Learn more about the partnership: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRcommunity #ScienceCollaboration #FluorescentLigands #BiotechStartup Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Annabelle Milner About Annabelle Milner Annabelle completed her undergraduate degree in Biomedical Sciences at the University of Bath. As part of the degree, she undertook a 1-year research-based placement at the Charles Perkins Centre in Sydney, investigating the effects of dietary carbohydrates on metabolic health with Dr. Jibran Wali. From here, she returned to the UK. She began her Ph.D. at Imperial College London with Prof Aylin Hanyaloglu, Prof Gary Frost, and Dr. Alastair Brown (Sosei Heptares), where she is currently a final year Ph.D. student. Annabelle’s Ph.D. work focuses on microbial-derived metabolites that signal through GPCRs expressed in the GI. In particular, she is looking at L- and D-lactate-activated HCAR1 signaling. She presented her Ph.D. work at the Society of Endocrinology Conference 2022 and was awarded the best oral poster prize. Outside the lab, she enjoys baking and swimming and has recently taken up paddle boarding. Annabelle Milner on the web Linkedin Researchgate Pubmed Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Re-cap of Endocrine Metabolic GPCR 2024 with the Organizers About Dr. Aylin Hanyaloglu Dr. Aylin Hanyaloglu has been a Principal Investigator at Imperial College London since 2007. She received her BSc in Human Biology from King’s College London in 1997, and while her Ph.D. commenced at the MRC Human Reproductive Sciences Centre, Edinburgh, a move to Perth, Australia resulted in her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western Australia. Dr. Hanyaloglu undertook her postdoctoral training at the University of California, San Francisco with Professor Mark von Zastrow where she identified novel core cellular machinery critical for G protein-coupled receptor trafficking and signaling. Her research focuses on understanding the fundamental cell biological mechanisms regulating GPCR activity, including spatial control of GPCR signaling and receptor crosstalk, and applying these mechanisms for distinct GPCRs in diverse physiological and pathophysiological systems, with particular focus on women's health, pregnancy, and nutrient sensing in the gut. Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes UK, Wellcome Trust, and the Medical Research Council. Dr. Aylin Hanyaloglu on the web LinkedIn Endocrine Metabolic GPCRs Researchgate Twitter Imperial College London Elsevier Loop Dr. GPCR About Dr. Caroline Gorvin "Dr. Caroline Gorvin is a Wellcome Trust & Royal Society Sir Henry Dale Fellow at the Institute of Metabolism and Systems Research, University of Birmingham. She obtained her PhD in 2012 from the University of Oxford, where her research focused on the cellular mechanisms by which mutations in a chloride-proton antiporter cause the renal disorder Dent’s disease. Caroline continued to undertake postdoctoral research in Oxford, investigating the signalling and trafficking of the G protein-coupled receptor (GPCR), calcium-sensing receptor, and its role in calcium homeostasis. Caroline moved to the University of Birmingham in 2018 to establish her research group investigating metabolic GPCRs. Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and bone metabolism." Dr. Caroline Gorvin on the web University of Birmingham Endocrine Metabolic GPCRs Society of Endocrinology Google Scholar ResearchGate Loop Twitter Dr. GPCR About Dr. Alejandra Tomas "Dr. Alejandra Tomas is a molecular cell biologist and Senior Lecturer at the Department of Metabolism, Digestion and Reproduction, Imperial College London. She obtained a PhD in Biochemistry from University College London and spent several years in Switzerland working on the study of membrane trafficking processes in pancreatic beta cells before returning to the UK, first to her Department at UCL and then to lead a laboratory at Imperial following the receipt of an MRC New Investigator Award in 2015." Dr. Alejandra Tomas on the web Imperial College London Endocrine Metabolic GPCRs ResearchGate Google Scholar LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Yamina Berchiche About this episode In this Episode 0 of the brand new Dr. GPCR podcast , your host and founder, Dr. Yamina Berchiche introduces the very first podcast dedicated to GPCRs researcher and their work. This podcast is part of the Dr. GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well as suppliers working on GPCRs by providing opportunities to connect, share, form trusting partnerships, grow, and thrive together to accelerate GPCR drug discovery and improve human health. Dr. Yamina Berchiche on the web - Website - LinkedIn - PubMed - Twitter - Facebook - Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Marta Filizola About Dr. Marta Filizola Dr. Marta Filizola is the Sharon & Frederick A. Klingenstein-Nathan G. Kase, MD Professor in the Departments of Pharmacological Sciences, Neuroscience, and Artificial Intelligence and Human Health, as well as the Dean of The Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, in New York, USA. The overall goal of her research program is to obtain rigorous mechanistic insights into the structure, dynamics, and function of important classes of membrane proteins and prominent drug targets, including G protein-coupled receptors (GPCRs), transporters, channels, and 3 integrins. To this end, her lab uses several computational structural biology tools and rational drug design approaches, ranging from molecular modeling, bioinformatics, cheminformatics, molecular dynamics simulations, free-energy perturbations, machine learning, etc. A native of Italy, she received her Bachelor’s and Master’s degrees in Chemistry from the University Federico II in Naples. She pursued a Ph.D. in Computational Chemistry at the Second University of Naples and a postdoctorate in Computational Biophysics at the Molecular Research Institute in California, USA. Dr. Marta Filizola on the web Icahn School of Medicine at Mount Sinai Filizola Lab Wikipedia Twitter Linkedin ResearchGate Google Scholar Orcid PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Registration & Coffee with light breakfast < Previous Session Next Session >

A breakthrough in GPCR imaging reveals a full native pancreatic islet and advances how GLP-1R can be visualized in tissue using chemical probes. Home → Flash News → Lighting up a native pancreatic islet isn’t just a technical win it’s a shift in what GPCR imaging can reveal Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal Published on December 8, 2025 Category Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery Previous Next Recent Articles

Home → Flash News → Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Published on April 22, 2025 Category Dr. GPCR Podcast Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Previous Next Recent Articles